Today's Peptide News — September 7, 2026

A review published in the journal Antibiotics surveys the current state of computational methods for discovering and designing antimicrobial peptides. With antibiotic resistance climbing worldwide, antimicrobial peptides remain one of the most promising classes of alternatives to conventional antibiotics. The paper catalogues recent advances in machine learning, molecular dynamics simulation, and structure-based design that are accelerating the identification of candidate peptides with potent activity against drug-resistant bacteria.

The review is particularly timely given the growing number of AI-driven peptide design platforms entering preclinical pipelines. For PeptideWiki readers, the paper offers a useful map of the computational toolkit now available to researchers working at the intersection of bioinformatics and peptide therapeutics.

A sweeping review published in the International Journal of Molecular Sciences in April 2026 examines the expanding role of therapeutic peptides in aesthetic medicine, metabolic disorders, and endocrine conditions. The paper covers FDA-approved peptide therapies alongside novel, unapproved compounds that are rapidly moving into preventive medicine and performance enhancement.

The review highlights how peptides sit in a pharmacological sweet spot between small molecules and large biologics, offering high potency and target specificity with generally favourable safety profiles. It provides a detailed assessment of clinical evidence, safety data, and future research directions, making it a strong reference for anyone tracking the peptide therapeutics landscape.

Researchers at Shinshu University in Japan have identified pterostilbene, a natural polyphenol found in blueberries and grapes, as a compound that helps skeletal muscle cells burn excess fat rather than storing it. The findings, published in Volume 83 of Food Bioscience on September 1, 2026, reveal a specific molecular mechanism: pterostilbene stabilises the PPARdelta protein by preventing its degradation through the ubiquitin-proteasome pathway, which in turn promotes fatty acid oxidation.

Excess lipid accumulation inside skeletal muscle cells is linked to insulin resistance, impaired glucose metabolism, and age-related muscle dysfunction. While pterostilbene is a polyphenol rather than a peptide, the PPARdelta pathway it targets is closely connected to peptide-mediated metabolic signalling, making the finding relevant to researchers exploring peptide-based approaches to metabolic health.

An FDA advisory committee has voted to recommend adding six unapproved peptides to the agency's 503A bulk compounding list. The peptides are BPC-157, KPV, TB-500, MOTS-c, epitalon, and semax, with proposed uses spanning wound healing, ulcerative colitis, weight loss, migraines, pain, and insomnia. One peptide, emideltide, was rejected.

The votes were described as closely split. FDA scientific reviewers opposed the additions, citing a lack of robust clinical evidence and unanswered safety questions. Supporters argued that regulated compounding would offer safer alternatives to the existing grey market, where these substances are already widely sold as research-grade products without human-use approval. The recommendation does not immediately legalise compounded versions. The FDA must decide whether to initiate rulemaking to formally add them to the 503A list, a process that could take a year or longer.

Eli Lilly announced positive topline results from TRIUMPH-1, the pivotal Phase 3 clinical trial evaluating retatrutide in adults with obesity or overweight with at least one weight-related comorbidity. At 80 weeks, the 12 mg dose group achieved an average weight loss of 28.3 percent, compared to roughly 2 percent in the placebo group. Among the 2,339 participants in the trial, 45.3 percent of those on the highest dose achieved 30 percent or greater weight loss, with a discontinuation rate of just 11.3 percent.

Retatrutide is a triple hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. These results represent the highest weight loss ever reported in a Phase 3 obesity trial. Lilly has also reported positive results from TRIUMPH-2 in type 2 diabetes (announced July 23, 2026) and expects seven additional Phase 3 readouts this year. A regulatory filing is anticipated in late 2026, with approval unlikely before 2027 or 2028.

The FDA posted warning letters on September 1, 2026 to multiple online peptide vendors, including Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations (doing business as Tex Peptides). The letters cite products including semaglutide, tirzepatide, retatrutide, survodutide, mazdutide, SS-31, PT-141, tesamorelin, and ipamorelin blends.

The sweep is part of a broader FDA enforcement campaign targeting the unregulated sale of research-grade peptides marketed for human use. The agency's action comes amid growing public interest in peptide therapies and increasing pressure on regulators to draw clearer lines between legitimate compounding and grey-market distribution.

The FDA granted accelerated approval to Yuviwel (navepegritide) on February 27, 2026, making it the first and only once-weekly treatment approved to increase linear growth in children aged 2 and older with achondroplasia who have open epiphyses. Yuviwel is a prodrug of C-type natriuretic peptide (CNP) that provides continuous systemic exposure to CNP over the weekly dosing interval, counteracting overactive FGFR3 signalling.

The pivotal ApproaCH trial demonstrated a statistically significant increase in annualised growth velocity of 1.5 cm per year versus placebo (5.9 versus 4.4 cm per year, p less than 0.0001). Ascendis Pharma has since received orphan drug exclusivity and launched the product in the United States. Continued approval may be contingent on confirmatory trial results.

Novo Nordisk's CagriSema, a once-weekly injection combining the GLP-1 agonist semaglutide with the amylin analogue cagrilintide, is currently under FDA review and could become the first approved therapy of its kind later in 2026. The combination achieved approximately 20 percent weight loss in its pivotal programme, positioning it as a next-generation obesity treatment that targets two distinct hormonal pathways.

CagriSema represents a broader industry trend toward combination peptide therapies. If approved, it would join an increasingly crowded obesity market alongside tirzepatide (Zepbound) and the pending retatrutide, each attacking the metabolic syndrome through different receptor combinations. The FDA decision is one of the most closely watched regulatory events in the peptide space this year.

Researchers have discovered that blocking a protein called SET prevented glioblastoma tumours from forming in preclinical models. The study, published in the May 2026 issue of Cancer Letters, found that glioblastoma cells suppress the tumour-suppressor enzyme PP2A using three proteins: ANP32A, CIP2A, and SET. Of the three, SET stood out because blocking it had the strongest effect on tumour formation.

The approach is designed to complement existing treatments rather than replace them. Researchers at Ohio State University are now investigating whether SET or other PP2A-suppressing proteins can be targeted safely in humans, and whether doing so improves the effectiveness of standard glioblastoma therapies including radiation.

New medical guidelines published in early September 2026 highlight how heart disease and chronic kidney disease can accelerate each other in a dangerous feedback loop. The guidelines emphasise that simple screening and early treatment could substantially reduce the compounding risks that arise when both conditions are present.

The recommendations call for routine kidney function testing in patients with cardiovascular disease, and cardiac risk assessment in patients with kidney disease. Early intervention with existing therapies, rather than novel drugs, is positioned as the most impactful change clinicians can make.

Researchers have discovered that susceptibility to rheumatoid arthritis may have its origins in prenatal development. The study found that the finger joints most commonly affected by the disease already show structural differences in tissue architecture compared to joints that are typically spared.

The finding suggests that the seeds of autoimmune joint disease may be sown during fetal development, long before any symptoms appear. If confirmed, this could open new avenues for early risk identification and potentially preventive intervention in people with a family history of the disease.